<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456777</url>
  </required_header>
  <id_info>
    <org_study_id>evcps</org_study_id>
    <nct_id>NCT04456777</nct_id>
  </id_info>
  <brief_title>Effect of Vortioxetine on Cognitive Symptoms in Patients With Schizophrenia</brief_title>
  <official_title>Effect of Vortioxetine on Cognitive Symptoms in Patients With</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alen Greš</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Hospital Centre Zagreb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research goals:&#xD;
&#xD;
        1. Examination of the relationship between the use of vortioxetine and cognitive efficacy&#xD;
           in patients with schizophrenia.&#xD;
&#xD;
        2. Examination of the association between the use of vortioxetine and the presence&#xD;
           depressive symptoms, physical and social anhedonia in patients with the disease from&#xD;
           schizophrenia.&#xD;
&#xD;
        3. Examining the association between vortioxetine use and quality of life&#xD;
&#xD;
      (functional recovery) in patients with schizophrenia&#xD;
&#xD;
      Expected results (hypotheses)&#xD;
&#xD;
        1. Patients with schizophrenia treated with additional therapy vortioxetine will show&#xD;
           better cognitive achievement in memory (short-term and long-term), attention, logical&#xD;
           reasoning and reasoning, speed of information processing, processing of visual and sound&#xD;
           information, language and speech in relation to patients without additional&#xD;
           intervention.&#xD;
&#xD;
        2. Patients with schizophrenia treated with additional therapy vortioxetine will have a&#xD;
           less pronounced presence of depressive symptoms, physical and social anhedonia in&#xD;
           relation to untreated patients with additional vortioxetine therapy.&#xD;
&#xD;
        3. Patients with schizophrenia who were treated with additional therapy vortioxetine will&#xD;
           have a better quality of life, ie. better functional recovery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first phase of the research, the development of the research protocol and obtaining it&#xD;
      will be done of his approval.&#xD;
&#xD;
      The second phase of the research will include patients with schizophrenia disorders based on&#xD;
      inclusive and exclusive criteria and a study will be conducted procedure. In the third phase&#xD;
      of the research, the obtained results are processed and analyzed.&#xD;
&#xD;
      The content of the dissertation will include an introduction, a goal with hypotheses,&#xD;
      methods, results, discussion, conclusions and literature. In the introduction, in addition to&#xD;
      current knowledge about schizophrenia and vortioxetine, it will be pointed out cognition&#xD;
      problem in patients with schizophrenia.&#xD;
&#xD;
      It will be defined and explained hypotheses and research objectives. In the chapter dedicated&#xD;
      to methodology, the number of respondents and a description will be presented study concepts,&#xD;
      presentation of statistical methods used for data processing The presentation of the results&#xD;
      obtained by this study will be presented textually, tabularly and using charts. The obtained&#xD;
      results will be commented and evaluated in the Discussion. Recent literature will be used&#xD;
&#xD;
      Randomization 1:1 will divide 120 patients with schizophrenia into two groups, each group&#xD;
      into 3 subgroups. One group of 60 patients (who are on monotherapy antipsychotics: new&#xD;
      generations: 20 patients will be on olanzapine, 20 patients on risperidone and 20 patients on&#xD;
      aripiprazole) will receive vortioxetine and the other control group of 60 patients (who is&#xD;
      also on monotherapy with new antipsychotics generations: 20 patients will be on olanzapine,&#xD;
      20 patients on risperidone and 20 patients on aripiprazole) will not receive vortioxetine.&#xD;
      Vortioxetine will be given in 10 mg dose (which can be reduced by 5 mg if needed in case of&#xD;
      poor tolerability)&#xD;
&#xD;
        1. Initial examination:&#xD;
&#xD;
           International mini neuropsychiatric interview (M.I.N.I.) publicly available, works&#xD;
           doctor General questionnaire - designed by a doctor Positive and negative syndrome&#xD;
           scales (PANSS) are publicly available, by a doctor The Calgary Depression Scale for&#xD;
           Schizophrenia (CDSS) is publicly available, it works doctor World Health Organization&#xD;
           for Quality of Life (WHOQOL-BREF) publicly available, works doctor Chapman (social&#xD;
           anhedonia and physical anhedonia) - publicly available, works doctor Wechsler WAIS IV&#xD;
           (subtests: numerical memory test; encryption test symbols) - available at Naklada Slap,&#xD;
           Zagreb, HR, by a clinical psychologist&#xD;
&#xD;
           Screening tests:&#xD;
&#xD;
             1. Mini-mental state (MMSE) or Folstein test - publicly available, by a doctor&#xD;
&#xD;
             2. Montreal Cognitive Assessment (MoCA) - publicly available, by a physician&#xD;
&#xD;
        2. At the end of the second month:&#xD;
&#xD;
           International mini neuropsychiatric interview (M.I.N.I.) publicly available, works&#xD;
           doctor Mini-mental state (MMSE) or Folstein test - publicly available, by a doctor&#xD;
           Montreal Cognitive Assessment (MoCA) - publicly available, by a doctor&#xD;
&#xD;
        3. At the end of the third month:&#xD;
&#xD;
      International mini neuropsychiatric interview (M.I.N.I.) publicly available, works doctor&#xD;
      Positive and negative syndrome scales (PANSS) are publicly available, by a doctor The Calgary&#xD;
      Depression Scale for Schizophrenia (CDSS) is publicly available, it works doctor World Health&#xD;
      Organization for Quality of Life (WHOQOL-BREF) publicly available, works doctor Chapman&#xD;
      (social anhedonia and physical anhedonia) - publicly available, works doctor Wechsler WAIS IV&#xD;
      (subtests: numerical memory test; encryption test)&#xD;
&#xD;
      - Available at Naklada Slap, Zagreb, HR, by a clinical psychologist Screening tests: a)&#xD;
      Mini-mental state (MMSE) or Folstein test - public&#xD;
&#xD;
      available, works doctor b) Montreal Cognitive Assessment (MoCA) - publicly available, by a&#xD;
      doctor It is expected: improvement of cognitive functions in relation to the initial&#xD;
      examination&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>better cognitive functions</measure>
    <time_frame>2 years</time_frame>
    <description>improvement of cognitive functions compared to initial examination</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cognitive Deficit</condition>
  <arm_group>
    <arm_group_label>1group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with vortioxetine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients without vortioxetine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>vortioxetine will be administreted for 3 months</description>
    <arm_group_label>1group</arm_group_label>
    <arm_group_label>2 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 50, informed consent signed, confirmed diagnosis of schizophrenia,&#xD;
             taking monotherapy with antipsychotics: aripiprazole, risperidone, paliperidone or&#xD;
             olanzapine, unchanged dose maintenance back at least 6 months, remission of psychotic&#xD;
             symptoms (PANSS ≤ 70), and that they do not have any of the exclusive criteria:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  taking benzodiazepines at doses equivalent to ≥ 10 mg diazepam, taking mood&#xD;
             stabilizers, antidepressants three months ago, abuse of addictions back three months,&#xD;
             suicide attempt back 6 months, suicidal, heteroaggressive, or other similar behavior&#xD;
             back 6 months, somatic comorbidities affecting cognitive functions (intellectual&#xD;
             disabilities, significant neurological disease or head trauma), pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alen Greš, MD</last_name>
    <phone>+385958845451</phone>
    <email>alengres@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marina Šagud, prof, MD</last_name>
    <email>marinasagud@mail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Hospital Centre Zagreb</investigator_affiliation>
    <investigator_full_name>Alen Greš</investigator_full_name>
    <investigator_title>Alen Greš,MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurobehavioral Manifestations</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

